DFTX Definium Therapeutics, Inc. - Common Shares
$44,55
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 6, 2026
Zakres 52 tyg.
$9–$50
87% of range
Ocena Analityków
BUY
23 analysts
Cena Docelowa
$67
+50% upside
P/E (TTM)
-21.6
ROE
-71.0%
Marża Zysku Netto
—
O Definium Therapeutics, Inc. - Common Shares Przegląd firmy z Wikipedii
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Czytaj więcej
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
History
MindMed was founded in May 2019 by Stephen Hurst and Jamon Rahn.
MindMed initially focused on developing treatments for opioid withdrawal and opioid use disorder with 18-MC, a non-hallucinogenic molecule based on the psychoactive alkaloid ibogaine. In June 2019, it acquired the 18-MC drug development program, previously funded by the National Institute on Drug Abuse, and in September began to prepare 18-MC for a Phase I FDA clinical trial to enable further clinical trials targeting opioid withdrawal and opioid use disorder.
MindMed was the first psychedelic pharmaceutical company to go public, listing on the Canadian NEO Exchange in March of 2020 through a reverse takeover with the Canadian gold mining company Broadway Gold Mining. It began trading on the Nasdaq as MNMD in April 2021 after being approved for an uplisting from the OTC Markets.
In a press release on June 9, 2021 MindMed announced that Jamon Rahn was stepping down both as the CEO and as a director on the board, to be replaced by then CDO Robert Barrow.
On February 26, 2021, MindMed closed its acquisition of digital health startup HealthMode. In connection with the acquisition, Daniel Karlin MD, CEO of HealthMode, was appointed to the position of CMO of the company.
On August 25, 2022, the first patient was dosed in a phase 2b trial for treatment of MM120 (now DT120) in generalized anxiety disorder (GAD). The study would go on to recruit 198 participants. The majority of trial participants experienced statistically significant improvements in their GAD scores, leading to the approval of multiple phase three human trials.
On January 12, 2026, MindMed rebranded to Definium Therapeutics.
Research
In March 2020, MindMed announced that it had partnered with NYU Langone to launch a clinical training program to train psychiatrists in psychedelic therapies and research to advance and deploy psychedelic medicines. The company committed $5 million to establish the center, which will also explore 18-MC and the use of drugs, including psilocybin-assisted therapy for alcohol use disorder.
In April 2020, the company entered into a long-term partnership with University Hospital Basel's Liechti Lab, gaining rights to more than ten years of the lab's data related to LSD, MDMA, and other psychedelic substances. The development of a novel compound designed to shorten the duration or stop an LSD experience that would allow LSD to be more widely used in a therapeutic environment was subsequently announced. Later that year a clinical trial studying the effects of DMT, the primary psychoactive ingredient in ayahuasca, and clinical trials combining MDMA and LSD were announced. A study to better understand and compare the altered states of consciousness induced by psilocybin and LSD began in August 2020,
and in October a Phase 1 study at the Liechti Lab on the acute dose dependent effects of LSD was completed. The results of the study were published by the American College of Neuropsychopharmacology in the journal Neuropsychopharmacology. In September 2021, further results were presented by Matthias Liechti, head of the Liechti Lab, at the INSIGHT Conference in Berlin. The results included the first clinical evidence on the comparative effects of LSD and psilocybin, stating 100mcg of LSD produced the same acute perceptual effects as a dose of 20 mg of psilocybin in healthy volunteers. Additionally, psilocybin taken after administering antidepressants for two weeks prior, was deemed safe, as well as reduced anxiety and blood pressure without hindering the psychedelic experience.
In December 2020, MindMed entered into an investigator-sponsored study agreement with Maastricht University in the Netherlands. The university provided facilities and personnel for a Phase 1 study to evaluate the effects of two low doses of LSD on mood, sleep and neuroplasticity.
In March 2024, the FDA granted breakthrough therapy designation to MindMed's form of LSD (MM120; now DT120) for the treatment of generalized anxiety disorder. This decision was influenced by a drug trial in which approximately half of the participants experienced significant relief from their symptoms. Positive results in clinical trials against general depression symptoms and generalized anxiety disorder were reported in 2026.
=== Ongoing clinical trials ===
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
DFTX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$44.55
Kapitalizacja Rynkowa
$4.40B
P/E (TTM)
-21.6
EPS (TTM)
$-2.06
Przychody (TTM)
—
Stopa dywidendy
—
ROE
-71.0%
D/E Dług/Kapitał
0.1
Zakres 52 tyg.
$9 – $50
DFTX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
—
EPS
$-2.06
2021-12-31
→
2025-12-31
Wolny przepływ pieniężny
—
Marże
—
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
DFTX
Mediana porównawcza
P/E (TTM)
-21.6
30.7
P/S (TTM)
1068.6
3.4
P/B
13.2
3.9
EV / EBITDA
-24.2
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
DFTX
Mediana porównawcza
ROA
-49.5%
-16.2%
ROE
-71.0%
-21.5%
ROIC
-44.6%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
DFTX
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
0.1
—
Current Ratio (Wskaźnik bieżący)
6.3
4.5
Quick Ratio (Wskaźnik Szybkości)
6.2
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
DFTX
Mediana porównawcza
Revenue YoY (Przychody R/R)
212.0%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
DFTX
Mediana porównawcza
DFTX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
23 analityków
- Mocne kupno 8 34,8%
- Kup 14 60,9%
- Trzymaj 1 4,3%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
16 analityków · 2026-08-16
Mediana
$66.00
← Poniżej wszystkich celów
$44.55
Niski
$52.00
Wysoki
$90.00
Średni cel
$66.00
+48,1%
Średnia cel
$67.00
+50,4%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.23%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-1.44 | $-0.56 | -0.88% |
| 31 marca 2026 | $-0.71 | $-0.50 | -0.21% |
| 31 grudnia 2025 | $-0.50 | $-0.50 | -0.00% |
| 30 września 2025 | $-0.78 | $-0.51 | -0.27% |
| 30 czerwca 2025 | $-0.50 | $-0.37 | -0.13% |
| 31 marca 2025 | $-0.27 | $-0.37 | 0.10% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| EWTX | $2.64B | -15.2 | — | — | -30.2% | — |
| INDV | — | 21.9 | 4.3% | 17.0% | -118.3% | 80.2% |
| MANE | — | — | — | — | 82.6% | — |
| ELVN | $915M | -8.4 | — | — | -21.9% | — |
| GPCR | $14.78B | -86.9 | — | — | -12.3% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $118M | $65M | $52M | $36M | $35M | $19M | |
| SG&A Expense | $49M | $39M | $42M | $30M | $59M | $14M | |
| Operating Expenses | $166M | $104M | $94M | $66M | $94M | $33M | |
| Operating Income | $-166M | $-104M | $-94M | $-66M | $-94M | $-33M | |
| Interest Expense | $5M | $2M | $920.0K | · | · | · | |
| Other Non-op | $-17M | $-5M | $-2M | $10M | $-339.0K | $-907.0K | |
| Pretax Income | $-184M | $-109M | $-96M | $-57M | $-94M | $-34M | |
| Income Tax | $0 | · | · | · | $-1M | · | |
| Net Income | $-184M | $-109M | $-96M | $-57M | $-93M | $-34M | |
| EPS (Basic) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| EPS (Diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | · | |
| Shares (Basic) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| Shares (Diluted) | 89,327,608 | 70,461,067 | 39,157,420 | 30,857,463 | 27,377,082 | · | |
| EBITDA | $-166M | $-104M | $-94M | $-66M | $-94M | · |
Bilans 20
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $274M | $100M | $142M | $134M | $80M | |
| Short-term Investments | $154M | $0 | · | · | · | · | |
| Prepaid Expense | $8M | $8M | $4M | $4M | $4M | $1M | |
| Current Assets | $419M | $282M | $104M | $146M | $137M | $82M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $0 | |
| Intangibles | · | $0 | $527.0K | $4M | $7M | · | |
| Other Non-current Assets | $862.0K | $613.0K | $224.0K | $331.0K | · | · | |
| Total Assets | $440M | $302M | $125M | $170M | $164M | $82M | |
| Accounts Payable | $5M | $2M | $4M | $2M | $4M | $2M | |
| Accrued Liabilities | $20M | $13M | $12M | $6M | $6M | $986.0K | |
| Current Liabilities | $67M | $39M | $32M | $18M | $10M | $3M | |
| Other Non-current Liabilities | $496.0K | · | $32.0K | $1M | $2M | · | |
| Total Liabilities | $108M | $61M | $46M | $19M | $12M | $6M | |
| Total Debt | $41M | $22M | $14M | · | · | · | |
| Common Stock | · | · | $0 | · | · | · | |
| Retained Earnings | $-583M | $-399M | $-290M | $-194M | $-138M | $-45M | |
| AOCI | $1M | $819.0K | $343.0K | $627.0K | $1M | $284.0K | |
| Stockholders' Equity | $332M | $241M | $78M | $151M | $152M | $76M | |
| Liabilities + Equity | $440M | $302M | $125M | $170M | $164M | $82M | |
| Shares Outstanding | 98,776,265 | 75,100,763 | 41,101,303 | 37,979,136 | 28,126,414 | · |
Przepływy pieniężne 9
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Deferred Tax | · | · | · | · | $-1M | · | |
| Amort. of Intangibles | $0 | $527.0K | $3M | $3M | $3M | $0 | |
| Operating Cash Flow | $-132M | $-79M | $-64M | $-50M | $-46M | $-24M | |
| Investing Cash Flow | $-152M | $0 | · | · | $-297.0K | · | |
| Stock Issued | $0 | $984.0K | $8M | $42M | $82M | $72M | |
| Net Stock Activity | $0 | $984.0K | $8M | $42M | $82M | · | |
| Financing Cash Flow | $267M | $253M | $22M | $59M | $99M | $97M | |
| Net Change in Cash | $-16M | $174M | $-42M | $9M | $53M | $73M | |
| Taxes Paid | $0 | · | · | · | · | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| Net Margin | · | · | -2052.6% | -3799.1% | 25915.3% | · | |
| Pretax Margin | · | · | -2052.6% | -3799.1% | 26237.6% | · | |
| EBITDA Margin | · | · | -2012.6% | -4436.9% | 26143.2% | · | |
| ROA | -49.5% | -50.9% | -65.0% | -34.0% | -75.8% | · | |
| ROE | -71.0% | -43.2% | -110.0% | -37.3% | -58.9% | · | |
| ROIC | -44.6% | · | · | · | -61.1% | · |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 | · | |
| Quick Ratio | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 | · | |
| Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.2 | · | · | · | |
| Interest Coverage | -30.3 | -45.5 | · | · | · | · |
Efektywność 1
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | -0.0 | · |
Stopy Wzrostu 1
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | 212.0% | · | · | · |
Wycena (TTM) 12
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $4M | $5M | $1M | $-359.0K | · | |
| Net Income TTM | $-184M | $-109M | $-96M | $-57M | $-93M | · | |
| Market Cap | $1.32B | $523M | · | · | · | · | |
| Enterprise Value | $952M | $271M | · | · | · | · | |
| P/E | -6.5 | -4.5 | · | · | · | · | |
| P/S | 321.2 | 126.9 | · | · | · | · | |
| P/B | 4.0 | 2.2 | · | · | · | · | |
| P / Tangible Book | 4.2 | 2.4 | · | · | · | · | |
| P / Cash Flow | -10.1 | -6.6 | · | · | · | · | |
| EV / EBITDA | -5.7 | -2.6 | · | · | · | · | |
| EV / Revenue | 231.1 | 65.8 | · | · | · | · | |
| Earnings Yield | -15.4% | -22.1% | · | · | · | · |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $49M | $41M | $34M | $31M | $30M | $23M | $22M | $17M | $15M | $12M | $12M | $13M | $15M | $13M | $9M | $8M | |
| SG&A Expense | $26M | $18M | $14M | $15M | $11M | $9M | $11M | $8M | $10M | $10M | $11M | $8M | $14M | $8M | $5M | $9M | |
| Operating Expenses | $75M | $59M | $48M | $46M | $41M | $32M | $32M | $25M | $24M | $22M | $22M | $22M | $29M | $21M | $14M | $17M | |
| Operating Income | $-75M | $-59M | $-48M | $-46M | $-41M | $-32M | $-32M | $-25M | $-24M | $-22M | $-22M | $-22M | $-29M | $-21M | $-14M | $-17M | |
| Interest Expense | $1M | $1M | $1M | $1M | $2M | $602.0K | $656.0K | $727.0K | $466.0K | $434.0K | $439.0K | $328.0K | $77.0K | $76.0K | · | · | |
| Other Non-op | $-84M | $-18M | $-3M | $-22M | $-2M | $9M | $-2M | $11M | $19M | $-32M | $-2M | $4M | $54.0K | $-4M | $9M | $498.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $-5M | $-16M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-159M | $-77M | $-50M | $-67M | $-43M | $-23M | $-35M | $-14M | $-6M | $-54M | $-24M | $-18M | $-29M | $-25M | $-5M | $-16M | |
| EPS (Basic) | $-1.44 | $-0.71 | $-0.51 | $-0.78 | $-0.50 | $-0.27 | $-0.14 | $-0.18 | $-0.08 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| EPS (Diluted) | $-1.44 | $-0.71 | $-0.43 | $-0.78 | $-0.50 | $-0.35 | $0.13 | $-0.27 | $-0.26 | $-1.14 | $-0.58 | $-0.45 | $-0.76 | $-0.65 | $-0.02 | $-0.56 | |
| Shares (Basic) | 110,684,720 | 108,790,941 | -166,973,440 | 85,885,516 | 85,347,677 | 85,067,855 | -127,221,454 | 77,909,441 | 71,912,323 | 47,860,757 | -77,216,232 | 39,720,007 | 38,576,394 | 38,077,251 | -54,828,395 | 29,296,333 | |
| Shares (Diluted) | 110,684,720 | 108,790,941 | -168,997,046 | 85,885,516 | 85,347,677 | 87,091,461 | -132,942,479 | 80,238,688 | 75,304,101 | 47,860,757 | -77,216,232 | 39,720,007 | 38,576,394 | 38,077,251 | -54,828,395 | 29,296,333 | |
| EBITDA | $-75M | $-59M | · | $-46M | $-41M | $-32M | · | $-25M | $-24M | $-22M | · | $-22M | $-29M | $-21M | · | $-17M |
Bilans 20
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $655M | $263M | $258M | $20M | $33M | $83M | $274M | $295M | $243M | $252M | $100M | $118M | $117M | $129M | $142M | $155M | |
| Short-term Investments | $429M | $111M | $154M | $189M | $150M | $130M | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $8M | $7M | $8M | $7M | $6M | $9M | $8M | $4M | $5M | $3M | $4M | $2M | $3M | $3M | $4M | $2M | |
| Current Assets | $1.09B | $381M | $419M | $216M | $189M | $222M | $282M | $299M | $248M | $255M | $104M | $120M | $120M | $132M | $146M | $157M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $527.0K | $1M | $2M | $3M | $4M | $4M | |
| Other Non-current Assets | $880.0K | $812.0K | $862.0K | $1M | $1M | $606.0K | $613.0K | $493.0K | $534.0K | $144.0K | $224.0K | $229.0K | $268.0K | $300.0K | $331.0K | · | |
| Total Assets | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Accounts Payable | $7M | $7M | $5M | $8M | $4M | $2M | $2M | $2M | $3M | $8M | $4M | $8M | $9M | $2M | $2M | $824.0K | |
| Accrued Liabilities | $37M | $25M | $20M | $19M | $15M | $11M | $13M | $9M | $8M | $10M | $12M | $10M | $10M | $7M | $6M | $7M | |
| Current Liabilities | $157M | $81M | $67M | $65M | $38M | $30M | $39M | $33M | $42M | $65M | $32M | $31M | $35M | $24M | $18M | $26M | |
| Other Non-current Liabilities | $549.0K | $559.0K | $496.0K | $519.0K | $543.0K | · | · | · | · | $15.0K | $32.0K | $349.0K | $992.0K | $1M | $1M | $1M | |
| Total Liabilities | $194M | $122M | $108M | $106M | $80M | $53M | $61M | $58M | $66M | $79M | $46M | $46M | $36M | $25M | $19M | $27M | |
| Total Debt | $36M | $41M | · | $40M | $41M | $22M | · | $24M | $24M | $14M | · | $14M | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | $0 | $0 | · | $0 | · | · | · | · | · | |
| Retained Earnings | $-819M | $-660M | $-583M | $-532M | $-465M | $-422M | $-399M | $-364M | $-350M | $-345M | $-290M | $-266M | $-248M | $-219M | $-194M | $-190M | |
| AOCI | $417.0K | $824.0K | $1M | $1M | $807.0K | $802.0K | $819.0K | $821.0K | $833.0K | $836.0K | $343.0K | $777.0K | $362.0K | $641.0K | $627.0K | $743.0K | |
| Stockholders' Equity | $919M | $279M | $332M | $131M | $185M | $223M | $241M | $262M | $202M | $196M | $78M | $96M | $106M | $130M | $151M | $154M | |
| Liabilities + Equity | $1.11B | $401M | $440M | $237M | $265M | $275M | $302M | $320M | $268M | $276M | $125M | $142M | $142M | $156M | $170M | $181M | |
| Shares Outstanding | 134,365,950 | 104,044,508 | 98,776,265 | 76,774,057 | 75,803,251 | 75,511,375 | 75,100,763 | 81,590,491 | 72,075,076 | 71,163,720 | 41,101,303 | 40,094,708 | 38,807,159 | 38,290,111 | 37,979,136 | 37,541,115 |
Przepływy pieniężne 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amort. of Intangibles | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $527.0K | $771.0K | $800.0K | $800.0K | $791.0K | $800.0K | $800.0K | |
| Operating Cash Flow | $-53M | $-43M | $-43M | $-30M | $-30M | $-29M | $-25M | $-17M | $-20M | $-17M | $-21M | $-17M | $-14M | $-13M | $-13M | $-9M | |
| Investing Cash Flow | $-317M | $42M | $35M | $15M | $-40M | $-162M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | · | · | $0 | $0 | · | · | $3M | $3M | $1M | $583.0K | $730.0K | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $583.0K | · | · | |
| Financing Cash Flow | $762M | $5M | $246M | $749.0K | $20M | $1M | $4M | $69M | $11M | $169M | $3M | $17M | $1M | $583.0K | $416.0K | $58M | |
| Net Change in Cash | $393M | $5M | $238M | $-13M | $-49M | $-191M | $-22M | $52M | $-9M | $153M | $-18M | $804.0K | $-13M | $-13M | $-12M | $49M |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| Net Margin | · | · | · | · | · | · | · | · | · | · | · | -1541.1% | -2222.0% | -1932.6% | · | -4579.2% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -4579.2% | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | · | · | -1858.6% | -2226.1% | -1624.8% | · | -4717.5% | |
| ROA | -23.1% | -22.8% | · | -24.2% | -16.0% | -8.5% | · | -5.9% | -2.9% | -25.2% | · | -11.1% | -21.1% | -16.3% | · | -18.2% | |
| ROE | -28.8% | -30.7% | · | -34.2% | -22.1% | -11.2% | · | -7.6% | -3.8% | -33.3% | · | -14.4% | -25.3% | -18.6% | · | -21.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | -11.1% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 4.7 | · | 3.3 | 5.0 | 7.3 | · | 9.0 | 5.9 | 3.9 | · | 3.9 | 3.4 | 5.5 | · | 6.0 | |
| Quick Ratio | 6.9 | 4.6 | · | 3.2 | 4.8 | 7.0 | · | 8.9 | 5.8 | 3.9 | · | 3.8 | 3.3 | 5.4 | · | 5.9 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| LT Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | · | · | |
| Interest Coverage | -60.9 | -47.6 | · | -35.8 | -17.5 | -53.4 | · | -34.1 | -52.5 | -51.2 | · | · | · | · | · | · |
Efektywność 1
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Wycena (TTM) 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $4M | · | $4M | $4M | $4M | · | $4M | $4M | $4M | · | $4M | $3M | $2M | · | $351.0K | |
| Net Income TTM | $-346M | $-210M | · | $-147M | $-86M | $-97M | · | $-92M | $-107M | $-126M | · | $-88M | $-87M | $-77M | · | $-69M | |
| Market Cap | $6.32B | $1.97B | · | $905M | $492M | $442M | · | $464M | $520M | $669M | · | · | · | · | · | · | |
| Enterprise Value | $5.27B | $1.63B | · | $736M | $350M | $251M | · | $193M | $301M | $431M | · | · | · | · | · | · | |
| P/E | -13.7 | -8.1 | · | -6.2 | -4.7 | -2.9 | · | -2.7 | -2.8 | -3.1 | · | · | · | · | · | · | |
| P/S | 1534.9 | 477.5 | · | 219.8 | 119.5 | 107.3 | · | 112.7 | 126.2 | 162.4 | · | · | · | · | · | · | |
| P/B | 6.9 | 7.1 | · | 6.9 | 2.7 | 2.0 | · | 1.8 | 2.6 | 3.4 | · | · | · | · | · | · | |
| P / Tangible Book | 7.0 | 7.6 | · | 8.2 | 3.0 | 2.2 | · | 1.9 | 2.9 | 3.8 | · | · | · | · | · | · | |
| P / Cash Flow | · | -46.1 | · | · | · | -15.0 | · | · | · | -40.3 | · | · | · | · | · | · | |
| EV / EBITDA | -70.2 | -27.6 | · | -16.1 | -8.6 | -7.8 | · | -7.8 | -12.3 | -19.4 | · | · | · | · | · | · | |
| EV / Revenue | 1280.5 | 396.7 | · | 178.8 | 85.0 | 61.0 | · | 46.9 | 73.0 | 104.6 | · | · | · | · | · | · | |
| Earnings Yield | -7.3% | -12.4% | · | -16.1% | -21.3% | -34.5% | · | -37.3% | -36.2% | -31.9% | · | · | · | · | · | · |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Marża Operacyjna % | — | — | -2012.6% | -4436.9% | 26143.2% |
| Zysk netto | $-184M | $-109M | $-96M | $-57M | $-93M |
| Rozwodniony EPS | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.1 | 0.1 | 0.2 | — | — |
| Wskaźnik bieżący | 6.3 | 7.2 | 3.2 | 8.2 | 13.2 |
| Wskaźnik Szybkości | 6.2 | 7.0 | 3.1 | 7.9 | 12.8 |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 387 emitentów · $4.0B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 167 | 28 | 108 | 69 | — |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary. Zmiana vs poprzedni kwartał nie pokazana: pokrycie zgłaszających różni się zbyt mocno między tymi dwoma kwartałami, aby można było dokonać wiarygodnego porównania.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | $338 165 292 | 7 188 888 | 8,35% | Akcje |
| Driehaus Capital Management LLC | $322 001 783 | 6 845 276 | 7,95% | Akcje |
| Capital World Investors | $252 497 690 | 5 367 723 | 6,24% | Akcje |
| FMR LLC | $188 434 384 | 4 005 833 | 4,65% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $148 941 987 | 3 165 629 | 3,68% | Akcje |
| STATE STREET CORP | $144 195 946 | 3 065 390 | 3,56% | Akcje |
| Capital International Investors | $139 398 806 | 2 963 410 | 3,44% | Akcje |
| Octagon Capital Advisors LP | $138 768 000 | 2 950 000 | 3,43% | Akcje |
| Deep Track Capital, LP | $129 360 000 | 2 750 000 | 3,20% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $104 294 124 | 2 217 137 | 2,58% | Akcje |
| Commodore Capital LP | $94 080 000 | 2 000 000 | 2,32% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $77 541 959 | 1 648 426 | 1,92% | Akcje |
| RA CAPITAL MANAGEMENT, L.P. | $70 560 000 | 1 500 000 | 1,74% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $69 922 796 | 1 486 454 | 1,73% | Akcje |
| Siren, L.L.C. | $66 772 951 | 1 419 493 | 1,65% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $65 216 256 | 1 386 400 | 1,61% | Opcja kupna |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $50 971 415 | 1 083 576 | 1,26% | Akcje |
| GOLDMAN SACHS GROUP INC | $49 226 937 | 1 046 491 | 1,22% | Akcje |
| Woodline Partners LP | $47 211 273 | 1 003 641 | 1,17% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $47 040 000 | 1 000 000 | 1,16% | Akcje |
| Boxer Capital Management, LLC | $46 969 440 | 998 500 | 1,16% | Akcje |
| CITADEL ADVISORS LLC | $43 623 579 | 927 372 | 1,08% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $43 362 319 | 921 818 | 1,07% | Akcje |
| Balyasny Asset Management L.P. | $42 217 365 | 897 478 | 1,04% | Akcje |
| AMERIPRISE FINANCIAL INC | $41 156 144 | 874 918 | 1,02% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $38 934 679 | 827 693 | 0,96% | Akcje |
| Holocene Advisors, LP | $37 470 841 | 796 574 | 0,93% | Akcje |
| AWM Investment Company, Inc. | $36 916 992 | 784 800 | 0,91% | Akcje |
| Polar Capital Holdings Plc | $36 561 981 | 777 253 | 0,90% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $34 082 124 | 1 803 287 | 0,84% | Akcje |
| EVENTIDE ASSET MANAGEMENT, LLC | $33 398 400 | 710 000 | 0,82% | Akcje |
| Qube Research & Technologies Ltd | $32 123 663 | 682 901 | 0,79% | Akcje |
| NEUBERGER BERMAN GROUP LLC | $29 068 697 | 617 957 | 0,72% | Akcje |
| Candriam S.C.A. | $28 874 744 | 614 425 | 0,71% | Akcje |
| ArrowMark Colorado Holdings LLC | $26 533 806 | 564 069 | 0,66% | Akcje |
| Catalio Capital Management, LP | $26 468 091 | 562 672 | 0,65% | Akcje |
| Blackstone Inc. | $26 418 228 | 561 612 | 0,65% | Akcje |
| Integral Health Asset Management, LLC | $25 872 000 | 550 000 | 0,64% | Akcje |
| BAMCO INC /NY/ | $24 465 880 | 520 108 | 0,60% | Akcje |
| FRANKLIN RESOURCES INC | $22 871 742 | 486 219 | 0,56% | Akcje |
| Point72 Asset Management, L.P. | $22 766 419 | 483 980 | 0,56% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $22 155 840 | 471 000 | 0,55% | Opcja sprzedaży |
| Ensign Peak Advisors, Inc | $21 925 626 | 466 106 | 0,54% | Akcje |
| GREAT POINT PARTNERS LLC | $19 992 000 | 425 000 | 0,49% | Akcje |
| JANE STREET GROUP, LLC | $19 940 256 | 423 900 | 0,49% | Opcja kupna |
| RTW INVESTMENTS, LP | $18 816 000 | 400 000 | 0,46% | Akcje |
| SILVERARC CAPITAL MANAGEMENT, LLC | $18 816 000 | 400 000 | 0,46% | Akcje |
| Cormorant Asset Management, LP | $18 816 000 | 400 000 | 0,46% | Akcje |
| Ally Bridge Group (NY) LLC | $18 816 000 | 400 000 | 0,46% | Opcja kupna |
| ASSETMARK, INC | $18 653 336 | 396 542 | 0,46% | Akcje |
| MARSHALL WACE, LLP | $18 196 013 | 386 820 | 0,45% | Akcje |
| Caption Management, LLC | $17 503 584 | 372 100 | 0,43% | Opcja kupna |
| ORBIMED ADVISORS LLC | $17 188 416 | 365 400 | 0,42% | Akcje |
| JANE STREET GROUP, LLC | $15 415 008 | 327 700 | 0,38% | Opcja sprzedaży |
| SILVERBACK ASSET MANAGEMENT LLC | $13 848 576 | 294 400 | 0,34% | Opcja kupna |
| CITADEL ADVISORS LLC | $13 547 520 | 288 000 | 0,33% | Opcja kupna |
| Tetragon Partners GP Ltd | $13 500 010 | 286 990 | 0,33% | Akcje |
| CITADEL ADVISORS LLC | $13 382 880 | 284 500 | 0,33% | Opcja sprzedaży |
| MILLENNIUM MANAGEMENT LLC | $12 516 215 | 266 076 | 0,31% | Akcje |
| Sofinnova Investments, Inc. | $12 037 677 | 255 903 | 0,30% | Akcje |
| PFM Health Sciences, LP | $11 713 901 | 249 020 | 0,29% | Akcje |
| HighVista Strategies LLC | $11 425 263 | 242 884 | 0,28% | Akcje |
| Trexquant Investment LP | $10 969 681 | 233 199 | 0,27% | Akcje |
| SEVEN GRAND MANAGERS, LLC | $10 584 000 | 225 000 | 0,26% | Akcje |
| Swiss National Bank | $10 405 248 | 221 200 | 0,26% | Akcje |
| Eversept Partners, LP | $10 216 382 | 217 185 | 0,25% | Akcje |
| TD Asset Management Inc | $9 852 998 | 209 460 | 0,24% | Akcje |
| ROYCE & ASSOCIATES LP | $9 810 239 | 208 551 | 0,24% | Akcje |
| SEB Asset Management AB | $9 796 249 | 208 254 | 0,24% | Akcje |
| SUPERSTRING CAPITAL MANAGEMENT LP | $8 856 785 | 188 282 | 0,22% | Akcje |
| EMERALD ADVISERS, LLC | $8 408 447 | 178 751 | 0,21% | Akcje |
| Aberdeen Group plc | $8 232 000 | 175 000 | 0,20% | Akcje |
| Tri Locum Partners LP | $7 667 332 | 162 996 | 0,19% | Akcje |
| RHUMBLINE ADVISERS | $7 436 824 | 158 096 | 0,18% | Akcje |
| Bank of New York Mellon Corp | $7 078 203 | 150 472 | 0,17% | Akcje |
| Seven Fleet Capital Management LP | $6 992 355 | 148 647 | 0,17% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $6 885 151 | 146 368 | 0,17% | Akcje |
| Brevan Howard Capital Management LP | $6 750 146 | 143 498 | 0,17% | Akcje |
| Rock Springs Capital Management LP | $6 735 516 | 143 187 | 0,17% | Akcje |
| SummitTX Capital, L.P. | $6 702 683 | 142 489 | 0,17% | Akcje |
| STEMPOINT CAPITAL LP | $6 450 313 | 137 124 | 0,16% | Akcje |
| BIT Capital GmbH | $6 027 282 | 128 131 | 0,15% | Akcje |
| FRED ALGER MANAGEMENT, LLC | $5 892 042 | 125 256 | 0,15% | Akcje |
| BlackRock, Inc. | $5 861 090 | 124 598 | 0,14% | Akcje |
| BANK OF AMERICA CORP /DE/ | $5 747 818 | 122 190 | 0,14% | Akcje |
| AdvisorShares Investments LLC | $5 709 762 | 121 381 | 0,14% | Akcje |
| EMERALD MUTUAL FUND ADVISERS TRUST | $5 703 553 | 121 249 | 0,14% | Akcje |
| Informed Momentum Co LLC | $5 688 453 | 120 928 | 0,14% | Akcje |
| Schonfeld Strategic Advisors LLC | $5 626 452 | 119 610 | 0,14% | Akcje |
| ALPS ADVISORS INC | $5 192 652 | 110 388 | 0,13% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $5 174 400 | 110 000 | 0,13% | Opcja sprzedaży |
| Russell Investments Group, Ltd. | $4 987 933 | 106 036 | 0,12% | Akcje |
| Data Collective IV GP, LLC | $4 720 464 | 100 350 | 0,12% | Akcje |
| Burkehill Global Management, LP | $4 704 000 | 100 000 | 0,12% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $4 539 830 | 96 510 | 0,11% | Akcje |
| KEYSTONE INVESTORS PTE LTD | $4 473 504 | 95 100 | 0,11% | Akcje |
| SIG BROKERAGE, LP | $4 384 128 | 93 200 | 0,11% | Opcja kupna |
| Pier Capital, LLC | $4 167 650 | 88 598 | 0,10% | Akcje |
| LPL Financial LLC | $4 051 837 | 86 136 | 0,10% | Akcje |
| Squadron Capital Management LLC | $3 998 400 | 85 000 | 0,10% | Akcje |
Insiderzy spółki 16 insiderów · 4 dyrektorzy generalni · 7 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Schond L. Greenway | Chief Financial Officer | 25 marca 2024 F | 211 057 | 0 | 0 | $0 |
| Miri Halperin Wernli | Executive President | 21 sierpnia 2024 M | 202 405 | 0 | 0 | $0 |
| Carrie Liao | Chief Accounting Officer | 25 marca 2025 S | 144 923 | 0 | 0 | $0 |
| Cynthia W. Hu | Chief Legal Officer&Secretary | 24 marca 2022 A | 1 200 000 | 0 | 0 | $0 |
| Roger Adsett | Dyrektor | 11 czerwca 2026 A | 3 555 | 0 | 0 | $0 |
| Roger Crystal | Dyrektor | 11 czerwca 2026 A | 24 289 | 0 | 0 | $0 |
| Suzanne Louise Bruhn | Dyrektor | 11 czerwca 2026 A | 24 289 | 0 | 0 | $0 |
| Andreas Krebs | Dyrektor | 11 czerwca 2026 A | 19 773 | 0 | 0 | $0 |
| Carol A Vallone | Dyrektor | 11 czerwca 2026 A | 21 210 | 0 | 0 | $0 |
| David W Gryska | Dyrektor | 11 czerwca 2026 A | 19 900 | 0 | 0 | $0 |
| Brigid Makes | Dyrektor | 1 czerwca 2022 A | 158 706 | 0 | 0 | $0 |
| Dan Karlin | — | 12 sierpnia 2026 A | 603 282 | 0 | 4 | $-748 876 |
| Robert Barrow | — | 12 sierpnia 2026 A | 1 473 246 | 0 | 4 | $-2 357 666 |
| Matthew T. Wiley | — | 12 sierpnia 2026 A | 237 133 | 0 | 1 | $-129 101 |
| Brandi Roberts | — | 12 sierpnia 2026 A | 271 987 | 0 | 1 | $-135 675 |
| Mark Sullivan | — | 12 sierpnia 2026 A | 383 071 | 0 | 4 | $-1 041 881 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 34 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,57% | 9 260 NS | 30 kwietnia 2026 | N-PORT |
| IHE · iShares Trust | 1,32% | 463 127 SH | 8 sierpnia 2026 | Dziennie |
| BBC · ETFis Series Trust I | 1,29% | 21 993 NS | 30 kwietnia 2026 | N-PORT |
| GSC · Goldman Sachs ETF Trust | 0,68% | 70 926 NS | 31 maja 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,51% | 4 214 NS | 31 maja 2026 | N-PORT |
| IBB · iShares Trust | 0,45% | 934 991 SH | 8 sierpnia 2026 | Dziennie |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,44% | 9 471 NS | 31 maja 2026 | N-PORT |
| IWO · iShares Trust | 0,37% | 1 186 034 SH | 8 sierpnia 2026 | Dziennie |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,36% | 139 235 SH | 8 sierpnia 2026 | Dziennie |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,34% | 5 935 SH | 8 sierpnia 2026 | Dziennie |
| VFMO · VANGUARD WELLINGTON FUND | 0,20% | 86 461 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,19% | 748 959 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,19% | 3 316 355 SH | 8 sierpnia 2026 | Dziennie |
| NUSC · Nushares ETF Trust | 0,14% | 83 684 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 0,12% | 3 685 NS | 31 maja 2026 | N-PORT |
| ESML · iShares Trust | 0,12% | 73 248 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,08% | 331 180 SH | 8 sierpnia 2026 | Dziennie |
| GSSC · Goldman Sachs ETF Trust | 0,08% | 31 411 NS | 31 maja 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,07% | 1 486 454 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,07% | 42 629 NS | 30 kwietnia 2026 | N-PORT |
| ITWO · ProShares Trust | 0,06% | 4 634 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,05% | 473 075 NS | 31 maja 2026 | N-PORT |
| WSML · iShares Trust | 0,05% | 6 763 SH | 8 sierpnia 2026 | Dziennie |
| UWM · ProShares Trust | 0,04% | 3 624 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 37 154 NS | 30 kwietnia 2026 | N-PORT |
| URTY · ProShares Trust | 0,03% | 3 665 NS | 31 maja 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 14 449 SH | 8 sierpnia 2026 | Dziennie |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 3 505 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,01% | 92 NS | 31 maja 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 10 703 SH | 8 sierpnia 2026 | Dziennie |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 40 894 NS | 31 maja 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 34 496 SH | 8 sierpnia 2026 | Dziennie |
| ITOT · iShares Trust | 0,01% | 161 945 SH | 8 sierpnia 2026 | Dziennie |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 55 178 NS | 31 maja 2026 | N-PORT |